Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi S, Schumann W, Petersen K, Landau B, Shulman G: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49. vsk, nro 12, s. 2063–9. PubMed:11118008doi:10.2337/diabetes.49.12.2063Artikkelin verkkoversio. (PDF)
Kim YD, Park KG, Lee YS, et al.: Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes, 2008, 57. vsk, nro 2, s. 306–14. PubMed:17909097doi:10.2337/db07-0381Artikkelin verkkoversio.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352. vsk, nro 9131, s. 854–65. PubMed:9742977doi:10.1016/S0140-6736(98)07037-8
Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F: Metformin treatment to prevent early puberty in girls with precocious pubarche. J. Clin. Endocrinol. Metab., 2006, 91. vsk, nro 8, s. 2888–91. PubMed:16684823doi:10.1210/jc.2006-0336
Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD.: Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med, 2003, 254. vsk, nro 5, s. 455–63. PubMed:14535967doi:10.1046/j.1365-2796.2003.01213.x
Ting R, Szeto C, Chan M, Ma K, Chow K: Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med, 2006, 166. vsk, nro 18, s. 1975–9. PubMed:17030830doi:10.1001/archinte.166.18.1975
Vigersky RA, Filmore-Nassar A, Glass AR: Thyrotropin suppression by metformin. J Clin Endocrinol Metab, 2006, 91. vsk, nro 1, s. 225–7. PubMed:16219720doi:10.1210/jc.2005-1210
Spiller HA, Quadrani DA: Toxic effects from metformin exposure. The Annals of pharmacotherapy, 2004, 38. vsk, nro 5, s. 776–80. PubMed:15031415doi:10.1345/aph.1D468
Guo PY, Storsley LJ, Finkle SN: Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Seminars in dialysis, 2006, 19. vsk, nro 1, s. 80–3. PubMed:16423187doi:10.1111/j.1525-139X.2006.00123.x
Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi S, Schumann W, Petersen K, Landau B, Shulman G: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49. vsk, nro 12, s. 2063–9. PubMed:11118008doi:10.2337/diabetes.49.12.2063Artikkelin verkkoversio. (PDF)
Kim YD, Park KG, Lee YS, et al.: Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes, 2008, 57. vsk, nro 2, s. 306–14. PubMed:17909097doi:10.2337/db07-0381Artikkelin verkkoversio.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352. vsk, nro 9131, s. 854–65. PubMed:9742977doi:10.1016/S0140-6736(98)07037-8
Bolen S, Feldman L, Vassy J, et al: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med, 2007, 147. vsk, nro 6, s. 386–99. PubMed:17638715
Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F: Metformin treatment to prevent early puberty in girls with precocious pubarche. J. Clin. Endocrinol. Metab., 2006, 91. vsk, nro 8, s. 2888–91. PubMed:16684823doi:10.1210/jc.2006-0336
Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD.: Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med, 2003, 254. vsk, nro 5, s. 455–63. PubMed:14535967doi:10.1046/j.1365-2796.2003.01213.x
Ting R, Szeto C, Chan M, Ma K, Chow K: Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med, 2006, 166. vsk, nro 18, s. 1975–9. PubMed:17030830doi:10.1001/archinte.166.18.1975
Vigersky RA, Filmore-Nassar A, Glass AR: Thyrotropin suppression by metformin. J Clin Endocrinol Metab, 2006, 91. vsk, nro 1, s. 225–7. PubMed:16219720doi:10.1210/jc.2005-1210
Spiller HA, Quadrani DA: Toxic effects from metformin exposure. The Annals of pharmacotherapy, 2004, 38. vsk, nro 5, s. 776–80. PubMed:15031415doi:10.1345/aph.1D468
Guo PY, Storsley LJ, Finkle SN: Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Seminars in dialysis, 2006, 19. vsk, nro 1, s. 80–3. PubMed:16423187doi:10.1111/j.1525-139X.2006.00123.x
Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med, 2002, 137. vsk, nro 1, s. 25–33. PubMed:12093242Artikkelin verkkoversio.
Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi S, Schumann W, Petersen K, Landau B, Shulman G: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49. vsk, nro 12, s. 2063–9. PubMed:11118008doi:10.2337/diabetes.49.12.2063Artikkelin verkkoversio. (PDF)
Kim YD, Park KG, Lee YS, et al.: Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes, 2008, 57. vsk, nro 2, s. 306–14. PubMed:17909097doi:10.2337/db07-0381Artikkelin verkkoversio.
Somogyi A, Stockley C, Keal J, Rolan P, Bochner F: Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol, 1987, 23. vsk, nro 5, s. 545–51. PubMed:3593625
